Antony Koblish left the role of Director at TELA Bio, Inc. As of November 6, 2026, TELA Bio, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 30, 2026 to August 31, 2026, naming 1 appointment and 1 departure (Form 8-K, August 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like TELA Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-31
- · In / out: Out · Person: Antony Koblish · Role: Director · 8-K, 2026-08-04
- · In / out: In · Person: Guido Neels · Role: Director · 8-K, 2026-04-30
TELA Bio, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-30 to 2026-08-31. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as TELA Bio, Inc. files it.
Layoffs on record: about 201 jobs, latest 2026-08-31 (layoff filings and notices).
Also on the record for TELA Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 12.94% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by SilverArc Capital Management, LLC | 4.8% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G, by SilverArc Capital Management, LLC | 4.8% of the class | 5%+ stakes | Source |
| June 9, 2026 | Stake report, Schedule 13D, by EW HEALTHCARE PARTNERS FUND 2, L.P. | 17.23% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Lytton, Laurence W. | 5.5% of the class | 5%+ stakes | Source |
| November 17, 2025 | Stake report, Schedule 13G/A, by EW Healthcare Partners Fund 2 GP, L.P. | 17.32% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Lytton, Laurence W. | 7.2% of the class | 5%+ stakes | Source |
| October 15, 2025 | Stake report, Schedule 13G/A, by GROW FUNDS, LLC. | — | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Lytton, Laurence W. | 8.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs TELA Bio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on TELA Bio, Inc. and the records around it.
TELA Bio, Inc. elsewhere on the record
- Layoff notices Aug 2026
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- GROW FUNDS, LLC. also filed stake reports on 2 other companies: BranchOut Food Inc. (Oct 2026), BUDA JUICE, INC. (Mar 2026)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), Fractyl Health Inc (May 2026)
- Lytton, Laurence W. also filed stake reports on 28 other companies: Retension Pharmaceuticals, Inc. (Oct 2026), Rank One Computing Corp (Aug 2026), MDxHealth SA (Aug 2026)
Watch TELA Bio, Inc.
Get an email when TELA Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on TELA Bio, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on TELA Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TELA Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-31 | Reported | not named in the filing | 8-K, 2026-08-31 | ||
| 2026-08-04 | Out | Director | 8-K, 2026-08-04 | ||
| 2026-04-30 | In | Director | 8-K, 2026-04-30 |
Who leads TELA Bio, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Antony Koblish, departure reported (filed 2026-08-04). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on TELA Bio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at TELA Bio, Inc., with the record behind each one.
Find candidates like Director at TELA Bio, Inc.Every change, in the filing's words
Reported
Effective on August 31, 2026, Roberto Cuca stepped down from his position as the Company's Chief Financial Officer, Chief Operating Officer, Corporate Secretary and principal financial officer.
- Mr. Cuca's departure will be treated as a termination without cause pursuant to his existing employment agreement.
Departing: Antony Koblish, Director
In addition, on August 3, 2026, Mr. Koblish, a member of the Board, tendered his resignation from the Board, effective as of 12:01 am ET on the Effective Date.
- Departure of Chief Executive Officer and Director On August 3, 2026, the Board of Directors (the "Board") of TELA Bio, Inc. (the "Company") determined that, Antony Koblish will no longer serve as the Company's Chief Executive Officer and the principal executive officer, effective on August 3, 2026 (the "Effective Date").
- Mr. Koblish's decision to resign from the Board did not result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.
- The Board and Company's decision that Mr. Koblish will no longer serve as the Company's Chief Executive Officer is not the result of any disagreement with Mr. Koblish on any matter relating to the Company's operations, policies, or practices.
- Appointment of Chief Executive Officer and Director On August 3, 2026, the Board of the Company approved the appointment of Heather Getz the Company's Chief Executive Officer and principal executive officer, effective on the Effective Date.
- In addition, on August 3, 2026, in connection with Mr. Koblish's resignation from the Board, the Board appointed Ms. Getz as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, effective immediately following the effectiveness of Mr. Koblish's resignation from the Board on the Effective Date.
Appointed: Guido Neels, Director
On April 29, 2026, in connection with the Resigning Directors' resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors, with terms expiring at the 2028 Annual Meeting of the Company (together, the " Incoming Directors "), in each case effective immediately following the 2026 Annual Meeting.
- Resignation of Directors On April 29, 2026, Doug Evans, Chairman of the Board of Directors (the "Board") of the Company, notified the Company and the Board that he will not stand for re-election at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") and will retire from the Board, including the Compensation Committee of the Board (the "Compensation Committee") and Audit Committee of the Board (the "Audit Committee"), effective immediately following the 2026 Annual Meeting.
- The Board has nominated Joseph Capper for election as a Class I director at the 2026 Annual Meeting, to serve for a term expiring at the 2029 Annual Meeting of the Company.
- Upon (i) Mr. Evan's resignation and (ii) Mr. Capper's election to the Board by the Company's stockholders at the 2026 Annual Meeting, Mr. Capper will be elected to serve as the Chairman of the Board until his successor is duly elected and qualified, or until his earlier resignation or removal.
- Mr. Capper is not expected to qualify as an independent director under applicable Nasdaq listing rules.
Tools for this story
Each opens in a new tab, filled in for TELA Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.